The role of dysadherin in gynecologic cancers has been investigated in five studies, all reporting high dysadherin mRNA expression or protein level as a marker of poor overall survival (22–26) (Table 1 and Supplementary Table I). Here, FXYD5 is linked to female reproductive organ cancer.